Breast cancer; Type 2 diabetes; Estrogen; Obesity; Metformin; Insulin
Abstract :
[en] Obesity and type 2 diabetes are two risk factors of breast cancer, especially after menopause. Underlying mechanisms are multiple and include hyperinsulinism due to insulin resistance (insulin, as insulin-like-growth factor -IGF-, is a growth factor), hyperleptinaemia associated with hypoadiponectinaemia, and high levels of estrogens resulting from aromatization of androgens in adipose tissue. In presence of type 2 diabetes associated with obesity, hyperglycaemia might provide energy substrate promoting tumour growth. These data have therapeutic implications with expected favourable effects of weight loss, resulting in a reduction of fat mass and insulin resistance, and the promising results recently reported with metformin contrasting with the negative effects of exogenous administration of high doses of insulin.
Disciplines :
Endocrinology, metabolism & nutrition Oncology
Author, co-author :
SCHEEN, André ; Centre Hospitalier Universitaire de Liège - CHU > Diabétologie,nutrition, maladies métaboliques
Beck, Emmanuel ; Université de Liège - ULiège > Département des sciences cliniques > Département des sciences cliniques
DE FLINES, Jenny ; Centre Hospitalier Universitaire de Liège - CHU > Diabétologie,nutrition, maladies métaboliques
RORIVE, Marcelle ; Centre Hospitalier Universitaire de Liège - CHU > Diabétologie,nutrition, maladies métaboliques
Language :
French
Title :
Obesite, insulinoresistance et diabete de type 2: facteurs de risque du cancer du sein.
Alternative titles :
[en] Obesity, insulin resistance and type 2 diabetes: risk factors for breast cancer
Publication date :
2011
Journal title :
Revue Médicale de Liège
ISSN :
0370-629X
eISSN :
2566-1566
Publisher :
Université de Liège. Revue Médicale de Liège, Liège, Belgium
Rose DP, Vona-Davis L. - Interaction between menopausal status and obesity in affecting breast cancer risk. Maturitas, 2010, 66, 33-38.
Schott S, Schneeweiss A, Sohn C. - Breast cancer and diabetes mellitus. Exp Clin Endocrinol Diabetes, 2010, 118, 673-677.
Renehan AG, Tyson M, Egger M, et al. - Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet, 2008, 37, 569-578. (Pubitemid 351232031)
Renehan AG, Soerjomataram I, Leitzmann MF. - Interpreting the epidemiological evidence linking obesity and cancer: A framework for population-attributable risk estimations in Europe. Eur J Cancer, 2010, 46, 2581-2592.
Grossmann ME, Ray A, Nkhata KJ, et al. - Obesity and breast cancer: status of leptin and adiponectin in pathological processes. Cancer Metastasis Rev, 2010, 29, 641-653.
Rose DP, Vona-Davis L. - Influence of obesity on breast cancer receptor status and prognosis. Expert Rev Anticancer Ther, 2009, 9, 1091-1101.
Vrieling A, Buck K, Kaaks R, Chang-Claude J. - Adult weight gain in relation to breast cancer risk by estrogen and progesterone receptor status : a meta-analysis. Breast Cancer Res Treat, 2010, 123, 641-649.
Protani M, Coory M, Martin JH. - Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat, 2010, 123, 627-635.
Maruthur NM, Bolen S, Brancati FL, Clark JM. - Obesity and mammography : a systematic review and meta-analysis. J Gen Intern Med, 2009, 24, 665-677.
Smith U, Gale EAM. - Does diabetes therapy influence the risk of cancer ? Diabetologia, 2009, 52, 1699-1708.
Giovannucci E, Harlan DM, Archer MC, et al. - Diabetes and cancer: A consensus report. Diabetes Care, 2010, 33, 1674-1685.
Simon D, Balkau B. - Diabetes mellitus, hyperglycaemia and cancer. Diabetes Metab, 2010, 36, 182-191.
Peairs KS, Barone BB, Snyder CF, et al. - Diabetes mellitus and breast cancer outcomes : a systematic review and meta-analysis. J Clin Oncol, 2011, 29, 40-46.
Erickson K, Patterson RE, Flatt SW, et al. - Clinically defined type 2 diabetes mellitus and prognosis in early-stage breast cancer. J Clin Oncol, 2011, 29, 54-60.
Renehan AG, Roberts DL, Dive C. - Obesity and cancer : pathophysiological and biological mechanisms. Arch Physiol Biochem, 2008, 114, 71-83. (Pubitemid 351998746)
Pollak M. - Insulin and insulin-like growth factor signaling in neoplasia. Nat Rev Cancer, 2008, 8, 915-928.
Godsland IF. - Insulin resistance and hyperinsulinaemia in the development and progression of cancer. Clin Sci, 2010, 118, 315-332.
Ray A, Cleary MP. - Leptin as a potential therapeutic target for breast cancer prevention and treatment. Expert Opin Ther Targets, 2010, 14, 443-451.
Vander Heiden MG, Cantley LC, Thompson CB. - Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science, 2009, 324, 626-631.
Johnson JA, Bowker SL. - Intensive glycaemic control and cancer risk in type 2 diabetes : a meta-analysis of major trials. Diabetologia, 2011, 54, 25-31.
Friedenreich CM. - Physical activity and breast cancer: review of the epidemiologic evidence and biologic mechanisms. Recent Results Cancer Res, 2011, 188, 125-139.
Sjöström L, Gummesson A, Sjöström CD, et al. - Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study) : a prospective, controlled intervention trial. Lancet Oncol, 2009, 10, 653-662.
Barbaric M, Brooks E, Moore L, Cheifetz O. - Effects of physical activity on cancer survival : a systematic review. Physiother Can, 2010, 62, 25-34.
Cleary MP, Ray A, Rogozina OP, et al. - Targeting the adiponectin:leptin ratio for postmenopausal breast cancer prevention. Front Biosci, 2009, 1, 329-357.
Wysocki PJ, Wierusz-Wysocka B. - Obesity, hyperinsulinemia and breast cancer: novel targets and a novel role for metformin. Expert Rev Mol Diagn, 2010, 10, 509-519.
Beck E, Scheen AJ. - Activité anticancéreuse de la metformine : nouvelles perspectives pour une vieille molécule. Rev Med Suisse, 2010, 6, 1601-1607.
Bowker SL, Yasui Y, Veugelers P, Johnson JA. - Glucose-lowering agents and cancer mortality rates in type 2 diabetes : assessing effects of time-varying exposure. Diabetologia, 2010, 53, 1631-1637.
Decensi A, Puntoni M, Goodwin P, et al. - Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila), 2010, 3, 1451-1461.
Bodmer M, Meier C, Krähenbühl S, et al. - Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care, 2010, 33, 1304-1308.
Bosco JL, Antonsen S, Sørensen HT, et al. - Metformin and incident breast cancer among diabetic women: a population-based case-control study in Denmark. Cancer Epidemiol Biomarkers Prev, 2011, 20, 101-111.
Ben Sahra I, Le Marchand-Brustel Y, Tanti JF, Bost F. - Metformin in cancer therapy: a new perspective for an old antidiabetic drug? Mol Cancer Ther, 2010, 9, 1092-1099.
Papanas N, Maltezos E, Mikhailidis DP. - Metformin and cancer : licence to heal? Expert Opin Investig Drugs, 2010, 19, 913-917.
Jiralerspong S, Palla SL, Giordano SH, et al. - Treatment with metformin gives better response to chemotherapy of breast cancer. J Clin Oncol, 2009, 27, 3297-3302.
Goodwin PJ, Ligibel JA, Stambolic V. - Metformin in breast cancer: time for action. J Clin Oncol, 2009, 27, 3271-3273.
Scheen AJ, Lefèbvre PJ. - Insuline glargine et cancer: une tempête dans un verre d'eau? Rev Med Liège, 2009, 64, 440-445.
Jonasson JM, Ljung R, Talbäck M, et al. - Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia, 2009, 52, 1745-1754.
Colhoun HM, SDRN Epidemiology Group. - Use of insulin glargine and cancer incidence in Scotland : a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia, 2009, 52, 1755-1765.
